Argus Upgrade Highlights Pfizer Pipeline

On March 2, equity research firm Argus upgraded Pfizer Inc. to Buy from Hold and set a price target of $35 per share. The firm cited what it described as encouraging progress in the company’s GLP-1 pipeline and robust programs in oncology and hematology.

According to Argus, these developments support greater confidence in Pfizer’s ability to grow both revenue and earnings in the period after 2028. The firm also pointed to accelerated research and development efforts, successful new product launches, and expectations for additional bolt-on business development initiatives beyond that timeframe.

Pfizer is also noted as being among the 14 Best Dividend Stocks to Invest in Under $50, reflecting its positioning in income-focused stock lists referenced in the reports.

Argus highlighted Pfizer’s GLP-1 pipeline as a key factor behind the rating change. While specific GLP-1 product candidates were not detailed, the firm characterized progress in this area as encouraging, suggesting it views these programs as potential contributors to future growth.

The analyst also emphasized what it called robust programs in oncology and hematology. These therapeutic areas are part of Pfizer’s broader research-based global biopharmaceutical operations, which span discovering, developing, manufacturing, marketing, selling, and distributing biopharmaceutical products worldwide.

The combination of GLP-1, oncology and hematology programs, together with ongoing R&D acceleration and product launches, was central to Argus’s more positive stance on Pfizer’s longer-term outlook.

On February 24, Pfizer announced that the US Food and Drug Administration granted full approval to BRAFTOVI (encorafenib) for certain colorectal cancer patients. The drug is approved for use in combination with Erbitux (cetuximab) and fluorouracil-based chemotherapy to treat adults with metastatic colorectal cancer carrying a BRAF V600E mutation.

The full approval followed results from the Phase 3 BREAKWATER trial, which showed improvements in both progression-free survival and overall survival for patients receiving the BRAFTOVI-based regimen. BRAFTOVI had previously received accelerated approval in December 2024, based on objective response rate data.

During the BREAKWATER trial, the treatment combinations demonstrated safety profiles consistent with the known effects of the drugs, and researchers did not identify new safety concerns. Some patients discontinued treatment because of side effects, but the number of such cases was described as relatively limited.

The BRAFTOVI combination therapy is also under regulatory review in Europe and has already been approved in several other countries, extending the reach of Pfizer’s oncology portfolio beyond the United States.

The articles note that while Pfizer is viewed as having potential as an investment, some commentators highlight that certain AI stocks may offer greater upside potential and less downside risk. This comparison is framed in the context of alternative opportunities, including AI names discussed in separate reports.

Within this landscape, Pfizer’s inclusion in a list of dividend stocks under $50 and the Argus upgrade underscore how recent pipeline progress, regulatory milestones, and ongoing R&D are shaping the company’s current perception among equity research and income-oriented investors.